Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study)

CONCLUSION: This real-world study shows that single-agent ibrutinib is an effective therapy for CLL, regardless of age and high-risk molecular features, consistent with clinical trials. Additionally, single-agent ibrutinib was well tolerated, with a low rate of cardiovascular events. This study also emphasized a high molecular testing rate of del(17p)/TP53 mutation and IGHV mutation status in clinical practice according to guideline recommendations.PMID:34511320 | DOI:10.1016/j.clml.2021.07.022

Source: Clinical Lymphoma and Myeloma - September 13, 2021 Category: Cancer & Oncology Authors: Pau Abrisqueta Javier Loscertales Maria Jos é Terol Ángel Ramírez Payer Macarena Ortiz Inmaculada P érez Carolina Cuellar-Garc ía Margarita Fern ández de la Mata Alicia Rodr íguez Ana Lario Julio Delgado Ana Godoy Jos é Mª Arguiñano Pérez M ª Source Type: research